

## Disclosures

### Personal Commercial (34)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<b>Self</b>			
AbbVie, Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">General Cardiology</a>
Abiomed	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">General Cardiology</a>
Alynlam	Research/Research Grants	Significant (>= \$5,000)	
Alynlam Pharm.	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">General Cardiology</a>
Anthos Therapeutic, LLC	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">General Cardiology</a>
Bayer	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">General Cardiology</a>
Boehringer Ingelheim	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">General Cardiology Other</a>
Boehringer Ingelheim	Research/Research Grants	Significant (>= \$5,000)	<a href="#">General Cardiology</a>
Boston Scientific	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">General Cardiology</a>
Bristol Myers Squibb	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">General Cardiology</a>
Bristol Myers Squibb	Research/Research Grants	Significant (>= \$5,000)	<a href="#">General Cardiology</a>
Cardionomic	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">General Cardiology</a>
CeleCor	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">General Cardiology</a>
Daiichi Sankyo	Research/Research Grants	Significant (>= \$5,000)	<a href="#">General Cardiology</a>
FDA	Research/Research Grants	Significant (>= \$5,000)	<a href="#">General Cardiology</a>
Janssen	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">General Cardiology</a>
Janssen Pharmaceuticals	Research/Research Grants	Significant (>= \$5,000)	<a href="#">General Cardiology</a>
Lilly	Research/Research Grants	Significant (>= \$5,000)	<a href="#">General Cardiology</a>
Medtronic Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">General Cardiology</a>
Merck & Co., Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">General Cardiology</a>
NephroSynergy	Consultant Fees/Honoraria	Significant (>= \$5,000)	
NIH	Research/Research Grants ‡ RACE CARs	Significant (>= \$5,000)	<a href="#">Arrhythmias and Clinical EP</a> <a href="#">General Cardiology</a>
Novartis Corporation	Research/Research Grants	Significant (>= \$5,000)	
Novo Nordisk Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">General Cardiology</a>
Pfizer	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">General Cardiology</a>
Pfizer	Research/Research Grants	Significant (>= \$5,000)	<a href="#">General Cardiology</a>
Philips	Research/Research Grants	Significant (>= \$5,000)	
Phillips	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Arrhythmias and Clinical EP</a>
REATA	Consultant Fees/Honoraria	Modest (< \$5,000)	
Roche	Research/Research Grants	Significant (>= \$5,000)	
Roche	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">General Cardiology</a>
Tenac.io	Stock	Modest (< \$5,000)	<a href="#">General Cardiology</a>
Veralox Therapeutics, Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Novartis Corporation	Research/Research Grants	Significant (>= \$5,000)	General Cardiology

## Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

## Personal Organizational or Other Non-Commercial (2)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<b>Self</b>			
FDA	Research/Research Grants	Significant (>= \$5,000)	
National Institutes of Health	Consultant Fees/Honoraria	Significant (>= \$5,000)	

## Clinical Trial Enroller (0)

No disclosures on record

## Institutional Financial Decision-Making Role (0)

No disclosures on record

## Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

### Certified Education Attestation | Signed on 10/31/2024

[URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement](http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement)

### Confidentiality, Disclosure and Assignment Agreement | Signed on 10/31/2024

[URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement](http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement)

### Embargo | Signed on 10/31/2024

[URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement](http://disclosures.acc.org/Public/Definition/EmbargoAgreement)

### On-Going Obligation Agreement | Signed on 10/31/2024

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.